Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ibrutinib tops chlorambucil against CLL

Publish date:: July 11, 2019

Key clinical point: Ibrutinib was superior to chlorambucil for patients with untreated chronic lymphocytic leukemia.

Major finding: Estimated 5-year progression-free survival for ibrutinib was 70%, compared with 12% for chlorambucil.

Study details: Long-term follow-up of a randomized, phase 3 trial in 269 adults with previously untreated CLL.

Disclosures: The trial was sponsored by Pharmacyclics with collaboration from Janssen Research & Development. Dr. Tedeschi reported advisory board activities with Janssen, AbbVie, and BeiGene.

Citation:

Tedeschi A et al. EHA Congress, Abstract S107.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,